A

AC Immune SA
D

ACIU

3.37000
USD
0.08
(2.43%)
Market Closed
Volume
1,412
EPS
-1
Div Yield
-
P/E
-8
Market Cap
333,438,355
OverviewSignalsIdeasNews
Related Instruments
    A
    ACRX
    0
    (0%)
    0.000000 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    D
    DRRX
    -0.12820
    (-11.45%)
    0.99180 USD
    J
    JAGX
    -0.08040
    (-7.73%)
    0.95960 USD
    S
    SNDX
    -0.955
    (-5.69%)
    15.825 USD
    T
    TGTX
    -1.325
    (-4.30%)
    29.515 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    T
    TRVN
    -2.02000
    (-44.99%)
    2.47000 USD
    More
News

Title: AC Immune SA

Sector: Healthcare
Industry: Biotechnology
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.